Recommended

Register now: Enhancing biopharma workflows with the power of UV/Vis spectroscopy webinar
Download our brand new eBook: A practical guide to single-use filtration in biopharma.
Join us as we look at how the outsourcing of buffers is helping biopharma drug manufacturers to streamline their processes.
Discover more on how Polpharma API meets evolving regulatory guidance around N-nitrosamines control in APIs with Waters’ high-performance analysis instruments.
Learn more about leveraging real-world data, the practical applications of AI and adopting configurable LC/NC solutions.
Download this compendium to discover how hot-melt extrusion can help to overcome pharmaceutical formulation challenges
news

Teva announces launch of generic Baraclude® Tablets, 0.5mg and 1mg, in the United States

Posted: 5 September 2014 | | No comments yet

Teva Pharmaceutical Industries Ltd. announces the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the United States…

TEVA LOGO

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announces the launch of the generic equivalent to Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

Baraclude® (Entecavir) Tablets, 0.5mg and 1mg, marketed by Bristol-Myers Squibb, had annual sales of approximately $328 million in the United States, according to IMS data as of June 2014.